Status:
RECRUITING
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Brain Cancer
Glioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recu...
Eligibility Criteria
Inclusion
- Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation
- May undergo radiation therapy
- Patient and/or guardian is able to provide written informed consent prior to study registration
- Age ≥ 18 years old
Exclusion
- Extreme claustrophobia that precludes MRI scan
- Known allergic reaction to Gd-DTPA
- Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines
- Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander).
- Pregnant or nursing female
- Unable to cooperate for MRI and/or radiation therapy planning
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00870129
Start Date
March 1 2009
End Date
September 1 2026
Last Update
October 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065